Medicure Dividende

Zukünftiges Wachstum Kriterienprüfungen 0/6

Medicure hat in der Vergangenheit keine Dividende gezahlt.

Wichtige Informationen

n/a

Dividendenausschüttung

n/a

Ausschüttungsquote

Durchschnittlicher Branchenertrag	2.8%
Nächster Dividendenzahlungstermin	n/a
Ex-Dividendendatum	n/a
Dividende pro Aktie	n/a
Gewinn pro Aktie	-CA$0.11
Erwartete Dividendenrendite in 3 Jahren	n/a

Aktuelle Dividendenentwicklung

Keine Aktualisierungen

Recent updates

Here's Why Shareholders Should Examine Medicure Inc.'s (CVE:MPH) CEO Compensation Package More Closely

Jun 15

Stabilität und Wachstum des Zahlungsverkehrs

Rufe Dividendendaten ab

Stabile Dividende: Es liegen keine ausreichenden Daten vor, um festzustellen, ob die Dividende je Aktie von MPH in der Vergangenheit stabil war.

Wachsende Dividende: Unzureichende Daten, um festzustellen, ob die Dividendenzahlungen von MPH gestiegen sind.

Dividendenrendite im Vergleich zum Markt

Medicure Dividendenrendite im Vergleich zum Markt

Wie sieht die Dividendenrendite von MPH im Vergleich zum Markt aus?
Segment	Dividendenrendite
Unternehmen (MPH)	n/a
Untere 25 % des Marktes (CA)	1.9%
Markt Top 25 % (CA)	6.6%
Branchendurchschnitt (Biotechs)	2.8%
Analystenprognose in 3 Jahren (MPH)	n/a

Bemerkenswerte Dividende: Es ist nicht möglich, die Dividendenrendite von MPH im Vergleich zu den unteren 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.

Hohe Dividende: Es ist nicht möglich, die Dividendenrendite von MPH im Vergleich zu den besten 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.

Gewinnausschüttung an die Aktionäre

Abdeckung der Erträge: Unzureichende Daten zur Berechnung der Ausschüttungsquote von MPH, um festzustellen, ob die Dividendenzahlungen durch die Gewinne gedeckt sind.

Barausschüttung an die Aktionäre

Cashflow-Deckung: Es ist nicht möglich, die Nachhaltigkeit der Dividende zu berechnen, da MPH keine Ausschüttungen gemeldet hat.

Medicure Dividende

Zukünftiges Wachstum Kriterienprüfungen 0/6

Wichtige Informationen

Aktuelle Dividendenentwicklung

Recent updates

Medicure Inc. Appoints Kimberly Kramchynsky, Known as Kim Kline as Director

First quarter 2024 earnings released

Now 24% undervalued after recent price drop

Estimating The Fair Value Of Medicure Inc. (CVE:MPH)

Medicure Inc., Annual General Meeting, May 28, 2024

Full year 2023 earnings released: CA$0.088 loss per share (vs CA$0.13 profit in FY 2022)

Medicure Inc. to Report Fiscal Year 2023 Results on Apr 08, 2024

Investors Don't See Light At End Of Medicure Inc.'s (CVE:MPH) Tunnel

New major risk - Share price stability

New major risk - Market cap size

Investor sentiment deteriorates as stock falls 24%

Investor sentiment deteriorates as stock falls 17%

Medicure Inc. Announces FDA Provides Complete Approval to Enroll Patients in Its Pivotal Phase 3 Trial for Treatment of Rare Pediatric Disease

Third quarter 2023 earnings released: EPS: CA$0.01 (vs CA$0.11 in 3Q 2022)

New minor risk - Profit margin trend

New minor risk - Share price stability

Investor sentiment deteriorates as stock falls 17%

We Ran A Stock Scan For Earnings Growth And Medicure (CVE:MPH) Passed With Ease

Second quarter 2023 earnings released: EPS: CA$0.02 (vs CA$0.067 loss in 2Q 2022)

Medicure Inc. to Report Q2, 2023 Results on Jul 28, 2023

New major risk - Share price stability

Investor sentiment deteriorates as stock falls 20%

Investor sentiment improves as stock rises 16%

First quarter 2023 earnings released: EPS: CA$0.03 (vs CA$0.047 in 1Q 2022)

Investor sentiment deteriorates as stock falls 22%

Investor sentiment improves as stock rises 20%

Full year 2022 earnings released: EPS: CA$0.13 (vs CA$0.071 loss in FY 2021)

Medicure Inc. Announces Resignation of Gerald McDole as Member of the Board of Directors

Investor sentiment improved over the past week

Founder recently bought CA$67k worth of stock

Medicure's (CVE:MPH) Earnings Are Weaker Than They Seem

Third quarter 2022 earnings released: EPS: CA$0.11 (vs CA$0.092 loss in 3Q 2021)

Medicure Inc. to Report Q3, 2022 Results on Nov 25, 2022

Insufficient new directors

Second quarter 2022 earnings released: CA$0.067 loss per share (vs CA$0.062 loss in 2Q 2021)

Investor sentiment improved over the past week

Medicure Inc. to Report Q2, 2022 Results on Aug 24, 2022

Investor sentiment improved over the past week

Medicure Inc. Appoints James Kinley as Director

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Medicure Inc. Appoints Haaris Uddin as Chief Financial Officer, Effective June 1, 2022

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Insufficient new directors

Medicure Inc., Annual General Meeting, Jun 16, 2022

Medicure Plans to Launch Innovative E-Commerce Pharmacy Platform Offering Hundreds of Medications Directly to Millions of Americans

Third quarter 2021 earnings: EPS and revenues miss analyst expectations

Second quarter 2021 earnings released: CA$0.06 loss per share (vs CA$0.002 profit in 2Q 2020)

Here's Why Shareholders Should Examine Medicure Inc.'s (CVE:MPH) CEO Compensation Package More Closely

CFO & Secretary has left the company

First quarter 2021 earnings released

Full year 2020 earnings released

New 90-day high: CA$1.70

Medicure Announces Early Completion of Enrollment for iSPASM

New 90-day high: CA$1.65

New 90-day high: CA$1.23

New 90-day high: CA$1.15

New 90-day low: CA$0.75

Medicure Inc. to Report Q3, 2020 Results on Nov 11, 2020

New 90-day low: CA$0.80

New 90-day low: CA$0.93

New 90-day high - CA$1.26

First half earnings released

Medicure Inc. to Report Q2, 2020 Results on Aug 11, 2020

Medicure Inc.(TSXV:MPH) dropped from S&P/TSX Venture Composite Index

Stabilität und Wachstum des Zahlungsverkehrs

Dividendenrendite im Vergleich zum Markt

Gewinnausschüttung an die Aktionäre

Barausschüttung an die Aktionäre

Entdecken Sie dividendenstarke Unternehmen